查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球缺血性視神經病變治療市場 - 全球產業分析、規模、份額、成長、趨勢、預測 (2031) - 按藥物類別、按給藥途徑、按疾病類型、按分銷管道、按地區
市場調查報告書
商品編碼
1397310

全球缺血性視神經病變治療市場 - 全球產業分析、規模、份額、成長、趨勢、預測 (2031) - 按藥物類別、按給藥途徑、按疾病類型、按分銷管道、按地區

Ischemic Optic Neuropathy Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:
出版日期: | 出版商: Fairfield Market Research | 英文 223 Pages | 商品交期: 2-5個工作天內

價格
簡介目錄

全球缺血性視神經病變治療市場規模逐漸擴大，預計2024年市場收入為2.006億美元，複合年增長率（CAGR）為5%，預計將達到286.1美元到 2031 年底將達到 100 萬。 有幾個關鍵因素推動缺血性視神經病變治療市場的成長。

人口老化的加劇以及人們對早期發現以防止症狀進一步惡化的重要性的認識不斷提高，正在推動人們對治療視神經疾病的手術和藥物療法的興趣，從而推動市場增長。這與加速發展有關。

視神經病變的流行正在推動這些疾病的治療需求並促進市場成長。 根據世界衛生組織 (WHO) 統計，全球有超過 13 億人患有視力障礙。 此外，驗光產業越來越傾向於非侵入性醫療程序，為市場進入者創造了有吸引力的機會。

由於先前核准的眼部植入物在眼科疾病治療中的使用越來越多，因此預計缺血性視神經病變治療市場將進一步成長。 已開發國家領先的製藥公司和藥品製造公司正在大力投資研發、基礎設施和先進的眼科治療，以搶佔不斷增長的眼病治療市場的份額，進一步加速全球市場的增長。我讓你做。

本報告調查了全球缺血性視神經病變治療市場，並提供了市場概述，以及按藥物類別、給藥途徑、疾病類型、分銷渠道、區域趨勢和進入市場的公司劃分的趨勢。我們提供競爭趨勢等等。

目錄

第 1 章執行摘要

第二章市場概述

  • 市場定義與細分
  • 市場動態
  • 價值鏈分析
  • 波特五力分析
  • 新冠肺炎 (COVID-19) 影響分析
  • 烏克蘭和俄羅斯之間衝突的影響
  • 經濟概況
  • 杵分析

第三章2018-2031年全球缺血性視神經病變治療市場前景

  • 2018-2031 年全球缺血性視神經病變治療市場展望（依藥物類別、價值（百萬美元））
  • 2018-2031 年全球缺血性視神經病變治療市場前景（按給藥途徑）、價值（百萬美元）
  • 2018-2031 年全球缺血性視神經病變治療市場前景（依疾病類型、價值（百萬美元））
  • 2018-2031 年全球缺血性視神經病變治療市場展望（按分銷管道）、價值（百萬美元）
  • 2018-2031 年全球缺血性視神經病變治療市場前景（按地區、價值（百萬美元））

第 4 章北美缺血性視神經病變治療市場前景，2018-2031

第五章歐洲缺血性視神經病變治療市場前景，2018-2031

第六章亞太地區缺血性視神經病變治療市場前景，2018-2031

第 7 章拉丁美洲缺血性視神經病變治療市場展望，2018-2031

第8章中東與非洲缺血性視神經病變治療市場前景，2018-2031

第九章競爭態勢

  • 藥物類別和給藥途徑的熱圖
  • 製造商和給藥途徑的熱圖
  • 2023 年公司市佔率分析
  • 競爭力儀表板
  • 公司簡介
    • Oracle Corporation
    • Merge Healthcare Incorporated
    • Medidata Solutions Inc.
    • PAREXEL International Corporation
    • BioClinica
    • MedNet Solutions, Inc.
    • Bio-Optronics, Inc.
    • DSG, Inc.
    • eClinForce, Inc.
    • Forte Research Systems, Inc.

第 10 章附錄

簡介目錄

The worldwide market for Ischemic Optic Neuropathy Treatment is poised for gradual expansion, with the market revenue estimated at US$ 200.6 Mn in 2024, and a projected Compound Annual Growth Rate (CAGR) of 5% expected to reach a valuation of US$ 286.1 Mn by the end of 2031. Several key factors are driving the growth of the market for the treatment of Ischemic Optic Neuropathy.

Growing Aging Population and Awareness Fuel Demand for Treatment

The increasing aging population and a rising awareness of the importance of early detection to prevent further deterioration of the condition have driven interest in surgical procedures and medications for treating optic nerve disorders, leading to accelerated market growth.

Prevalence of Optic Nerve Disorders Spurs Market Demand

The prevalence of optic nerve disorders is boosting the demand for treatments for these conditions, contributing to market growth. According to the World Health Organization (WHO), over 1.3 billion individuals worldwide suffer from eyesight disorders. Additionally, the growing preference for non-invasive medical procedures in the optometric industry is creating attractive opportunities for market players.

R&D Investments Drive Market Expansion

The Ischemic Optic Neuropathy Treatment market is expected to grow further due to increased use of previously approved ocular implants in managing ophthalmology disorders. Leading pharmaceutical and drug manufacturing companies from developed countries are heavily investing in research and development, infrastructure, and advanced ophthalmology therapeutics to capture a share of the growing eye disorder treatment market, further accelerating global market growth.

Factors Driving Market Growth:

  • 1. Increasing Adoption of Foreign Direct Investment: The rise in foreign direct investment between European countries, Japan, China, and the ASEAN nations has attracted foreign players to explore markets in India and China, expanding their product reach. Domestic players are also exploring new product development strategies in response to these opportunities.
  • 2. Increasing Pool of Diabetic Patients: Ischemic optic neuropathy is commonly associated with diabetes. The increasing prevalence of risk factors such as hypercholesterolemia, diabetes, and hypertension is driving the incidence of this condition.
  • 3. Rising Prevalence of Risk Factors: Several risk factors, including reduced blood flow to the optic nerve, increased intraocular pressure, constricted arteries, and others, contribute to ischemic optic neuropathy. These risk factors are associated with various medical conditions, increasing the likelihood of disease development.

Impact on Global Ischemic Optic Neuropathy Treatment Market:

"Severe Side Effects Associated with High-Dose Corticosteroids Medication": High-dose corticosteroids, commonly used as a first-line treatment for ischemic optic neuropathy, can have severe side effects, including heart attack, kidney failure, lung damage, and more. These side effects can adversely affect patients' health and impede market growth.

"High Medication Costs in Underdeveloped Economies": Licensed medications for the treatment of ischemic optic neuropathy can be expensive, making them unaffordable for patients in underdeveloped economies.

Why is the U.S. Ischemic Optic Neuropathy Treatment Market Booming?

"Better Reimbursement Policies": The United States boasts a well-established healthcare infrastructure and facilities, and it currently holds the largest market share globally. Favorable reimbursement policies and high incomes contribute to the growth of the market in the country.

Will Germany Be a Lucrative Market for Manufacturers?

"Highest Number of Older People in the Region and Robust Healthcare System": Germany's sophisticated and organized healthcare system, along with its focus on research and development in the treatment of eye-related disorders, makes it an attractive market for companies worldwide.

Competitive Landscape:

Manufacturers are keen on diversifying their product portfolios by introducing innovative products and securing approvals from various governmental agencies.

Key Companies' Profiled:

  • AbbVie Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline
  • Pfizer Inc.
  • Teva Pharmaceuticals
  • Bausch Health Companies Inc.
  • F. Hoffmann-La Roche AG
  • Bayer AG
  • Sanofi A.S.
  • Bristol-Myers Squibb and Company

Market Segmentation

Drug Class:

  • Corticosteroids
  • Antimetabolites
  • Anticoagulants
  • Serotonin and norepinephrine reuptake inhibitors (SNRIs)
  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

Route of Administration:

  • Oral
  • Injectable

Disease Type:

  • Posterior ischemic optic neuropathy
  • Anterior ischemic optic neuropathy

Arteritic AION (A-AION)

Non-Arteritic AION (NA-AION)

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Pharmacies

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Ischemic Optic Neuropathy Treatment Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Ischemic Optic Neuropathy Treatment Market Outlook, 2018 - 2031

  • 3.1. Global Ischemic Optic Neuropathy Treatment Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Cloud based Ischemic Optic Neuropathy Treatment
      • 3.1.1.2. Web based Ischemic Optic Neuropathy Treatment
      • 3.1.1.3. On-premise Ischemic Optic Neuropathy Treatment
  • 3.2. Global Ischemic Optic Neuropathy Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Pharmaceuticals
      • 3.2.1.2. Clinical Research Organizations (CROs)
      • 3.2.1.3. Healthcare Providers
  • 3.3. Global Ischemic Optic Neuropathy Treatment Market Outlook, by Disease Type, Value (US$ Mn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Enterprise based Ischemic Optic Neuropathy Treatment
      • 3.3.1.2. Site based Ischemic Optic Neuropathy Treatment
  • 3.4. Global Ischemic Optic Neuropathy Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. Hospital Pharmacies
      • 3.4.1.2. Retail Pharmacies
      • 3.4.1.3. Drug Stores
      • 3.4.1.4. Online Pharmacies
  • 3.5. Global Ischemic Optic Neuropathy Treatment Market Outlook, by Region, Value (US$ Mn), 2018 - 2031
    • 3.5.1. Key Highlights
      • 3.5.1.1. North America
      • 3.5.1.2. Europe
      • 3.5.1.3. Asia Pacific
      • 3.5.1.4. Latin America
      • 3.5.1.5. Middle East & Africa

4. North America Ischemic Optic Neuropathy Treatment Market Outlook, 2018 - 2031

    • 4.1.1. Key Highlights
      • 4.1.1.1. Cloud based Ischemic Optic Neuropathy Treatment
      • 4.1.1.2. Web based Ischemic Optic Neuropathy Treatment
      • 4.1.1.3. On-premise Ischemic Optic Neuropathy Treatment
  • 4.2. North America Ischemic Optic Neuropathy Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Pharmaceuticals
      • 4.2.1.2. Clinical Research Organizations (CROs)
      • 4.2.1.3. Healthcare Providers
  • 4.3. North America Ischemic Optic Neuropathy Treatment Market Outlook, by Disease Type, Value (US$ Mn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Enterprise based Ischemic Optic Neuropathy Treatment
      • 4.3.1.2. Site based Ischemic Optic Neuropathy Treatment
  • 4.4. North America Ischemic Optic Neuropathy Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. Hospital Pharmacies
      • 4.4.1.2. Retail Pharmacies
      • 4.4.1.3. Drug Stores
      • 4.4.1.4. Online Pharmacies
  • 4.5. North America Ischemic Optic Neuropathy Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 4.5.1. Key Highlights
      • 4.5.1.1. U.S. Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 4.5.1.2. U.S. Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 4.5.1.3. U.S. Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 4.5.1.4. U.S. Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 4.5.1.5. Canada Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 4.5.1.6. Canada Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 4.5.1.7. Canada Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 4.5.1.8. Canada Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Ischemic Optic Neuropathy Treatment Market Outlook, 2018 - 2031

  • 5.1. Europe Ischemic Optic Neuropathy Treatment Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Cloud based Ischemic Optic Neuropathy Treatment
      • 5.1.1.2. Web based Ischemic Optic Neuropathy Treatment
      • 5.1.1.3. On-premise Ischemic Optic Neuropathy Treatment
  • 5.2. Europe Ischemic Optic Neuropathy Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Pharmaceuticals
      • 5.2.1.2. Clinical Research Organizations (CROs)
      • 5.2.1.3. Healthcare Providers
  • 5.3. Europe Ischemic Optic Neuropathy Treatment Market Outlook, by Disease Type, Value (US$ Mn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Enterprise based Ischemic Optic Neuropathy Treatment
      • 5.3.1.2. Site based Ischemic Optic Neuropathy Treatment
  • 5.4. Europe Ischemic Optic Neuropathy Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Hospital Pharmacies
      • 5.4.1.2. Retail Pharmacies
      • 5.4.1.3. Drug Stores
      • 5.4.1.4. Online Pharmacies
  • 5.5. Europe Ischemic Optic Neuropathy Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 5.5.1. Key Highlights
      • 5.5.1.1. Germany Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 5.5.1.2. Germany Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.3. Germany Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.4. Germany Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.5. U.K. Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 5.5.1.6. U.K. Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.7. U.K. Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.8. U.K. Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.9. France Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 5.5.1.10. France Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.11. France Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.12. France Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.13. Italy Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 5.5.1.14. Italy Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.15. Italy Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.16. Italy Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.17. Turkey Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 5.5.1.18. Turkey Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.19. Turkey Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.20. Turkey Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.21. Russia Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 5.5.1.22. Russia Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.23. Russia Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.24. Russia Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 5.5.1.25. Rest of Europe Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 5.5.1.26. Rest of Europe Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 5.5.1.27. Rest of Europe Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 5.5.1.28. Rest of Europe Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Ischemic Optic Neuropathy Treatment Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Ischemic Optic Neuropathy Treatment Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Cloud based Ischemic Optic Neuropathy Treatment
      • 6.1.1.2. Web based Ischemic Optic Neuropathy Treatment
      • 6.1.1.3. On-premise Ischemic Optic Neuropathy Treatment
  • 6.2. Asia Pacific Ischemic Optic Neuropathy Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Pharmaceuticals
      • 6.2.1.2. Clinical Research Organizations (CROs)
      • 6.2.1.3. Healthcare Providers
  • 6.3. Asia Pacific Ischemic Optic Neuropathy Treatment Market Outlook, by Disease Type, Value (US$ Mn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Enterprise based Ischemic Optic Neuropathy Treatment
      • 6.3.1.2. Site based Ischemic Optic Neuropathy Treatment
  • 6.4. Asia Pacific Ischemic Optic Neuropathy Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. Hospital Pharmacies
      • 6.4.1.2. Retail Pharmacies
      • 6.4.1.3. Drug Stores
      • 6.4.1.4. Online Pharmacies
  • 6.5. Asia Pacific Ischemic Optic Neuropathy Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 6.5.1. Key Highlights
      • 6.5.1.1. China Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 6.5.1.2. China Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.3. China Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 6.5.1.4. China Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.5.1.5. Japan Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 6.5.1.6. Japan Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.7. Japan Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 6.5.1.8. Japan Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.5.1.9. South Korea Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 6.5.1.10. South Korea Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.11. South Korea Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 6.5.1.12. South Korea Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.5.1.13. India Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 6.5.1.14. India Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.15. India Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 6.5.1.16. India Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.5.1.17. Southeast Asia Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 6.5.1.18. Southeast Asia Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.19. Southeast Asia Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 6.5.1.20. Southeast Asia Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 6.5.1.21. Rest of Asia Pacific Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 6.5.1.22. Rest of Asia Pacific Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 6.5.1.23. Rest of Asia Pacific Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 6.5.1.24. Rest of Asia Pacific Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Ischemic Optic Neuropathy Treatment Market Outlook, 2018 - 2031

  • 7.1. Latin America Ischemic Optic Neuropathy Treatment Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Cloud based Ischemic Optic Neuropathy Treatment
      • 7.1.1.2. Web based Ischemic Optic Neuropathy Treatment
      • 7.1.1.3. On-premise Ischemic Optic Neuropathy Treatment
  • 7.2. Latin America Ischemic Optic Neuropathy Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Pharmaceuticals
      • 7.2.1.2. Clinical Research Organizations (CROs)
      • 7.2.1.3. Healthcare Providers
  • 7.3. Latin America Ischemic Optic Neuropathy Treatment Market Outlook, by Disease Type, Value (US$ Mn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Enterprise based Ischemic Optic Neuropathy Treatment
      • 7.3.1.2. Site based Ischemic Optic Neuropathy Treatment
  • 7.4. Latin America Ischemic Optic Neuropathy Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Hospital Pharmacies
      • 7.4.1.2. Retail Pharmacies
      • 7.4.1.3. Drug Stores
      • 7.4.1.4. Online Pharmacies
  • 7.5. Latin America Ischemic Optic Neuropathy Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 7.5.1. Key Highlights
      • 7.5.1.1. Hardware
      • 7.5.1.2. Services
  • 7.6. Latin America Ischemic Optic Neuropathy Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 7.6.1. Key Highlights
      • 7.6.1.1. Brazil Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 7.6.1.2. Brazil Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 7.6.1.3. Brazil Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 7.6.1.4. Brazil Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 7.6.1.5. Mexico Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 7.6.1.6. Mexico Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 7.6.1.7. Mexico Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 7.6.1.8. Mexico Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 7.6.1.9. Argentina Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 7.6.1.10. Argentina Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 7.6.1.11. Argentina Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 7.6.1.12. Argentina Ischemic Optic Neuropathy Treatment Market by Distribution Type, Value (US$ Mn), 2018 - 2031
      • 7.6.1.13. Rest of Latin America Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 7.6.1.14. Rest of Latin America Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 7.6.1.15. Rest of Latin America Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 7.6.1.16. Rest of Latin America Ischemic Optic Neuropathy Treatment Market by Distribution Type, Value (US$ Mn), 2018 - 2031
    • 7.6.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Ischemic Optic Neuropathy Treatment Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Ischemic Optic Neuropathy Treatment Market Outlook, by Drug Class, Value (US$ Mn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Cloud based Ischemic Optic Neuropathy Treatment
      • 8.1.1.2. Web based Ischemic Optic Neuropathy Treatment
      • 8.1.1.3. On-premise Ischemic Optic Neuropathy Treatment
  • 8.2. Middle East & Africa Ischemic Optic Neuropathy Treatment Market Outlook, by Route of Administration, Value (US$ Mn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Pharmaceuticals
      • 8.2.1.2. Clinical Research Organizations (CROs)
      • 8.2.1.3. Healthcare Providers
  • 8.3. Middle East & Africa Ischemic Optic Neuropathy Treatment Market Outlook, by Disease Type, Value (US$ Mn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Enterprise based Ischemic Optic Neuropathy Treatment
      • 8.3.1.2. Site based Ischemic Optic Neuropathy Treatment
  • 8.4. Middle East & Africa Ischemic Optic Neuropathy Treatment Market Outlook, by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. Hospital Pharmacies
      • 8.4.1.2. Retail Pharmacies
      • 8.4.1.3. Drug Stores
      • 8.4.1.4. Online Pharmacies
  • 8.5. Middle East & Africa Ischemic Optic Neuropathy Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 8.5.1. Key Highlights
      • 8.5.1.1. GCC Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 8.5.1.2. GCC Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 8.5.1.3. GCC Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 8.5.1.4. GCC Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.5.1.5. South Africa Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 8.5.1.6. South Africa Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 8.5.1.7. South Africa Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 8.5.1.8. South Africa Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.5.1.9. Egypt Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 8.5.1.10. Egypt Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 8.5.1.11. Egypt Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 8.5.1.12. Egypt Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.5.1.13. Nigeria Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 8.5.1.14. Nigeria Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 8.5.1.15. Nigeria Ischemic Optic Neuropathy Treatment Market Disease Type, Value (US$ Mn), 2018 - 2031
      • 8.5.1.16. Nigeria Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
      • 8.5.1.17. Rest of Middle East & Africa Ischemic Optic Neuropathy Treatment Market by Drug Class, Value (US$ Mn), 2018 - 2031
      • 8.5.1.18. Rest of Middle East & Africa Ischemic Optic Neuropathy Treatment Market by Route of Administration, Value (US$ Mn), 2018 - 2031
      • 8.5.1.19. Rest of Middle East & Africa Ischemic Optic Neuropathy Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 8.5.1.20. Rest of Middle East & Africa Ischemic Optic Neuropathy Treatment Market by Distribution Channel, Value (US$ Mn), 2018 - 2031
    • 8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Drug Class vs Route of Administration Heatmap
  • 9.2. Manufacturer vs Route of Administration Heatmap
  • 9.3. Company Market Share Analysis, 2023
  • 9.4. Competitive Dashboard
  • 9.5. Company Profiles
    • 9.5.1. Oracle Corporation
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Drug Class Portfolio
      • 9.5.1.3. Financial Overview
      • 9.5.1.4. Business Strategies and Development
    • 9.5.2. Merge Healthcare Incorporated
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Drug Class Portfolio
      • 9.5.2.3. Financial Overview
      • 9.5.2.4. Business Strategies and Development
    • 9.5.3. Medidata Solutions Inc.
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Drug Class Portfolio
      • 9.5.3.3. Financial Overview
      • 9.5.3.4. Business Strategies and Development
    • 9.5.4. PAREXEL International Corporation
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Drug Class Portfolio
      • 9.5.4.3. Financial Overview
      • 9.5.4.4. Business Strategies and Development
    • 9.5.5. BioClinica
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Drug Class Portfolio
      • 9.5.5.3. Financial Overview
      • 9.5.5.4. Business Strategies and Development
    • 9.5.6. MedNet Solutions, Inc.
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Drug Class Portfolio
      • 9.5.6.3. Financial Overview
      • 9.5.6.4. Business Strategies and Development
    • 9.5.7. Bio-Optronics, Inc.
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Drug Class Portfolio
      • 9.5.7.3. Financial Overview
      • 9.5.7.4. Business Strategies and Development
    • 9.5.8. DSG, Inc.
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Drug Class Portfolio
      • 9.5.8.3. Financial Overview
      • 9.5.8.4. Business Strategies and Development
    • 9.5.9. eClinForce, Inc.
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Drug Class Portfolio
      • 9.5.9.3. Financial Overview
      • 9.5.9.4. Business Strategies and Development
    • 9.5.10. Forte Research Systems, Inc.
      • 9.5.10.1. Company Overview
      • 9.5.10.2. Drug Class Portfolio
      • 9.5.10.3. Financial Overview
      • 9.5.10.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations